All In Biotech

Drug Trial Radar · NCT01431339

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regimen (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Last checked: Nov 19, 2026Latest source record: Feb 12, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 739 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

739

Actual

Start

Jul 2011

Primary completion

Nov 2012

Study completion Dec 2012

Sponsor

Sponsor type
Industry
First posted
Sep 9, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy) of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral linezolid) for the treatment of patients with a suspected or proved gram-positive bacterial skin or skin structure infections.

Conditions

  • Abscess
  • Wound Infection
  • Surgical Site Infection
  • Cellulitis

Interventions

  • IV DalbavancinDrug

    IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8

  • Vancomycin/LinezolidDrug

    IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg every 12 hours). Total duration of therapy is 10-14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Early Clinical EfficacyTime frame: After 48-72 hours of therapy

Locations

137 sites in 14 countries. Site status is shown where the registry gives one.

  • Durata Clinical Site

    Montgomery, Alabama

  • Durata Clinical Site

    Anaheim, California

  • Durata Clinical Site

    Buena Park, California

  • Durata Study Site

    Chula Vista, California

  • Durata Clinical Site

    Long Beach, California

  • Durata Study Site

    Los Angeles, California

  • Durata Study Site

    Norwalk, California

  • Durata Study Site

    Oxnard, California

  • Durata Study SIte

    San Diego, California

  • Durata Study Site

    Stockton, California

  • Durata Clinical Site

    Boyton Beach, Florida

  • Durata Clinical Site

    Fort Meyers, Florida

  • Durata Clinical Site

    Miami, Florida

  • Durata Study Site

    Orlando, Florida

  • Durata Clinical Site

    Saint Cloud, Florida

  • Durata Clinical Site

    Augusta, Georgia

  • Durata Study Site

    Columbus, Georgia

  • Durata Clinical Site

    Chicago, Illinois

  • Durata Study Site

    Baton Rouge, Louisiana

  • Durata Study Site

    New Orleans, Louisiana

  • Durata Study Site

    Shreveport, Louisiana

  • Durata Study Site

    Zachary, Louisiana

  • Durata Study Site

    Las Vegas, Nevada

  • Durata Study Site

    Springfield, Ohio

  • Durata Study Site

    Philadelphia, Pennsylvania

  • Durata Study Site

    Austin, Texas

  • Durata Clinical Site

    Austin, Texas

  • Durata Clinical Site

    Houston, Texas

  • Durata Study Site

    Richmond, Texas

  • Durata Study Site

    Middleton, Wisconsin

  • Durata Study Site

    Pleven, Bulgaria

  • Durata Study Site

    Plovdiv, Bulgaria

  • Durata Study Site

    Sevlievo, Bulgaria

  • Durata Study Site

    Sofia, Bulgaria

  • Durata Study Site

    Sofia, Bulgaria

  • Durata Study Site

    Sofia, Bulgaria

  • Durata Study Site

    Sofia, Bulgaria

  • Durata Study Site

    Kohtla-Järve, Estonia

  • Durata Clinical Site

    Kohtla-Järve, Estonia

  • Durata Clinical Site

    Tallinn, Estonia

Showing 40 of 137 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.